Close Menu

Lung Cancer

News and reporting on lung cancer.

The company said it has signed a term sheet for an option to license patent applications related to knocking down beta III-tubulin using RNAi, an approach that has been shown to sensitize cancer cells to chemotherapy.

Based on a small, preliminary study, an NHGRI-led team concluded that smokers respond quite well to genetic test results provided online — a finding that could have implications for helping smokers kick the habit.

The technology "has broad potential uses in the development of cancer prognostic assays including response predictions to therapeutics as well as research tools and reagents," PrognosDx said in a statement.

DNA mutations and microRNA profiles of lung cancer tumors differ between patients who have smoked compared with those who haven't, a National Cancer Institute researcher reported at AACR.

The firm reported no revenues, but it managed to cut its net loss as it prepares to launch its LungExpress Dx product in the US later this year.

The companies — Rosetta Genomics, MDRNA, and Tekmira Pharmaceuticals — have all seen their shares more than double since Dec. 31, significantly outperforming the Nasdaq Biotechnology Index.

A separate deal under which Prometheus agreed to acquire 2 million shares of Rosetta at $4 per share has also been completed.

NCI Director John Niederhuber said last week that the institute plans to expand the Cancer Genome Atlas project to 20 to 25 major tumor types, and to apply next-generation sequencing to at least 100 tumor samples for each of several types of childhood cancers under the TARGET initiative.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

Based on the results of the study, the company has assembled a panel of six protein biomarkers with the ability to detect non-small cell lung cancer in patients with 94 percent sensitivity and 93 percent specificity. The company is hoping to launch the test by 2012.

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.